Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study.
about
One site mutation disrupts dimer formation in human DPP-IV proteinsDiscovery of gastric inhibitory polypeptide and its subsequent fate: Personal reflectionsThe crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanismPrevention of obesity-induced renal injury in male mice by DPP4 inhibition.Release of GLP-1 and PYY in response to the activation of G protein-coupled bile acid receptor TGR5 is mediated by Epac/PLC-ε pathway and modulated by endogenous H2S.Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes.Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes.Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).Gut peptides in the treatment of diabetes mellitus.Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review.The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management.Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence.MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice.Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes.Vildagliptin preserves the mass and function of pancreatic β cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes.Characterisation of human dipeptidyl peptidase IV expressed in Pichia pastoris. A structural and mechanistic comparison between the recombinant human and the purified porcine enzyme.Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline.The dipeptidyl peptidase IV inhibitor vildagliptin suppresses development of neuropathy in diabetic rodents: Effects on peripheral sensory nerve function, structure and molecular changes.GIP-(3–42) does not antagonize insulinotropic effects of GIP at physiological concentrationsInhibitors of proline-specific dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes
P2860
Q24305361-6DC8058D-F4BA-4FBF-A0AF-B4485A95290CQ26749226-28F79CEE-1C65-42D7-A554-7D36A52E2BCCQ27640960-3A59A286-1C80-44A9-8966-1B70168B041AQ33610654-27D73413-D49B-4573-A32E-A7648E366E58Q34441486-F69C11EB-71E8-4D0D-8DDD-BE18B0B07709Q34620636-9E9DB163-D295-4990-BEFA-47345476E384Q34648201-F54E5A90-101A-486C-92DF-21DDC1F3D899Q35607330-38AD8CA5-CB86-4801-BEE2-D51614B02D9AQ35688209-0B663735-DF22-4BE8-B71B-B23D2A193603Q35772029-BB9F97A6-181E-4368-AB44-DC7F4BD2D831Q35962745-48A142EE-64C0-403E-8B5D-38671D04F868Q36187070-16CAC2D3-BBE3-4AFE-BD87-4C64D7CAD8FFQ36693199-46D286DF-E993-4637-93A5-E069FCDB8CADQ36735761-DFD88704-3F9E-49C4-9B39-F7FE79CC1A2AQ37900690-ED982118-5DD1-4D5F-825D-ECF0CCEF8EF7Q38302500-ECF856E0-F302-4663-ACDD-5C62B8C1D0D4Q38603506-A558DCA4-13E6-476B-B224-23D0D55D7126Q43070817-56E752D1-ACFD-408B-A133-1AB741260FE0Q44726066-590A42ED-CE7E-4D46-BF77-54FD15C9E113Q48379621-E4DFEF29-046A-431A-968B-7B1B74694EFBQ48713671-9C019747-2BCF-472F-BF5B-C60E472D9000Q58448506-D33E37A1-4378-4661-859B-87DE90772185Q58864225-524970A4-0262-4115-A3D5-82BDC9E604A8
P2860
Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Long-term treatment with dipep ...... -hyperinsulinemic clamp study.
@ast
Long-term treatment with dipep ...... -hyperinsulinemic clamp study.
@en
type
label
Long-term treatment with dipep ...... -hyperinsulinemic clamp study.
@ast
Long-term treatment with dipep ...... -hyperinsulinemic clamp study.
@en
prefLabel
Long-term treatment with dipep ...... -hyperinsulinemic clamp study.
@ast
Long-term treatment with dipep ...... -hyperinsulinemic clamp study.
@en
P2093
P1433
P1476
Long-term treatment with dipep ...... -hyperinsulinemic clamp study.
@en
P2093
Christopher H S McIntosh
Hans-Ulrich Demuth
John A Pospisilik
Raymond A Pederson
Sara G Stafford
P304
P356
10.2337/DIABETES.51.9.2677
P407
P577
2002-09-01T00:00:00Z